News Features Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses Shelley Wood December 23, 2019
News Features Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019 Todd Neale December 10, 2019
News Conference News AHA 2019 Dapagliflozin Has Benefits Across Heart Failure Subgroups Todd Neale November 17, 2019
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for October 2019 Todd Neale October 31, 2019
News Daily News Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes L.A. McKeown October 21, 2019
News Daily News ARB Use Linked to Suicide in New Study, but Is the Finding Real? Michael O'Riordan October 18, 2019
News Conference News HFSA 2019 Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention L.A. McKeown September 24, 2019
News Conference News HFSA 2019 DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF L.A. McKeown September 16, 2019
News Conference News ESC 2019 DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics Shelley Wood September 01, 2019
News Daily News RAS Inhibition After TAVR Gains More Support, but RCT Still Needed Todd Neale July 29, 2019
News Industry News U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure June 26, 2019
News Conference News ESC Heart Failure 2019 Weaning Off Diuretics in Stable Heart Failure? ReBIC-1 Hints at Possibilities Shelley Wood May 28, 2019
News Conference News ACC 2019 New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin Shelley Wood March 26, 2019
News Daily News How HF Drugs Help and Harm Female Patients: A Call for Sex-Specific Reporting Shelley Wood February 26, 2019